In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?
This month marks the 100-year anniversary of BCG, still the only approved vaccine against the lethal pathogen. But there are new vaccines for this wily foe on the horizon.